Kura Oncology to Participate in the 5th Annual Gateway Conference
02 September 2016 - 9:30PM
Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage
biopharmaceutical company, today announced its participation in the
2016 Gateway Conference. Troy Wilson, Ph.D., J.D., President and
Chief Executive Officer, is scheduled to present an overview of the
company on Wednesday, September 7, 2016 at 12:00 p.m. PDT (3:00
p.m. EDT). The conference will be held from September 7-8, 2016 in
San Francisco.
A live audio webcast and replay will be available
in the Investors section of Kura Oncology's corporate website at
www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. The company’s pipeline consists of small
molecules that target cancer signaling pathways where there is a
strong scientific and clinical rationale to improve outcomes by
identifying those patients most likely to benefit from
treatment. Kura Oncology’s lead drug candidate is tipifarnib,
a farnesyl transferase inhibitor, which is currently being studied
in multiple Phase 2 clinical trials. The preclinical pipeline
includes KO-947, an ERK inhibitor, and a menin-MLL program. For
additional information about Kura Oncology, please visit the
company’s website at www.kuraoncology.com.
CONTACT INFORMATION
INVESTOR CONTACT:
Robert H. Uhl
Managing Director
Westwicke Partners, LLC
(858) 356-5932
robert.uhl@westwicke.com
CORPORATE COMMUNICATIONS CONTACT:
Mark Corbae
Vice President
Canale Communications
(619) 849-5375
mark@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2024 to May 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From May 2023 to May 2024